Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Scientists at St. Jude Children's Research Hospital are mining the genetic code to better match patients and medications now and in the future.
For many years, St. Jude researchers have been investigating the connection between genetics and pediatric cancer. Those approaches continue to have dramatic implications for clinical care.
St. Jude boosts cure rates for older teens with acute lymphoblastic leukemia.
New research from St. Jude Children’s Research Hospital and the Children’s Oncology Group ties the genetic variation characteristic of Native American ancestry to higher odds cancer will return and highlights a strategy to ease the racial disparities in survival.
Research led by St. Jude Children’s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer
With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children’s Research Hospital a prestigious grant to focus on anticancer agent research in children. The five-year, $8.6 million grant is titled “PAAR4Kids—Pharmacogenomics of Anticancer Agents Research in Children.”
St. Jude clinicians announce the best survival rates ever reported for ALL. What could be better than that? Achieving those rates without the use of cranial irradiation.
Michael Kastan, MD, PhD, and Mary Relling, PharmD, of St. Jude Children’s Research Hospital, have been elected to the Institute of Medicine (IOM), a prestigious branch of the National Academy of Sciences.
Scientists at St. Jude Children’s Research Hospital have identified inherited variations in two genes that account for 37 percent of childhood acute lymphoblastic leukemia (ALL), including a gene that may help predict drug response.
How can we design more effective chemotherapy for childhood leukemia? St. Jude researchers look at the big picture—and find intriguing answers.
Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS).
Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.
Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia.
Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia
Investigators at St. Jude Children's Research Hospital have discovered inherited variations in certain genes that make children with acute lymphoblastic leukemia (ALL) susceptible to the toxic side effects caused by chemotherapy medications.
The outcome of chemotherapy treatment for acute lymphoblastic leukemia (ALL) depends not only on the acquired genetic make-up of the leukemic cells, but on genes that children inherit from their parents.
Pharmacogenomics, is a cutting-edge technology for studying how populations of specific genes control an individual's response to drug therapy.